Skip to the reading

Peptide care, in plain words

Bring the whole quote

GHK-Cu evidence

GHK-Cu needs a question about the form.

Is the offer a cosmetic for skin appearance, a medicine mixed for a patient, or a shot? Ask what the product is for and how it is used before comparing its claims with its price.

Name the ingredient before the benefit.

GHK-Cu holds copper in a peptide, a short chain assembled from protein’s building blocks; a skin label may call it copper tripeptide-1.

The September 30, 2026 U.S. approval check found no approved medicine containing GHK-Cu, regardless of form.

The U.S. agency called FDA is the Food and Drug Administration; its work includes reviewing medicines for approval.

What changes when the form changes?

A cosmetic on skin

A cream sold only to improve skin’s appearance is a cosmetic; these products and ingredients needed no FDA approval before sale, apart from added colours, under rules checked September 30, 2026.

Skin gets some of its strength from a protein called collagen.

As of September 30, 2026, FDA treated a cream claiming to increase collagen as a drug or medical device, rather than just a cosmetic.

Those are legal categories for products intended to change how the body works, not a claim that the cream is a piece of equipment.

A medicine used without a shot

A compounded medicine is mixed by a licensed pharmacist or doctor, or by a business that has registered with FDA to produce batches of medicines.

FDA oversees that kind of business; an ordinary pharmacy is mainly overseen by its state pharmacy board.

The distinction here is whether it is sold as a cosmetic or made as a medicine. “Without a shot” describes how it is used, not the exact product.

As of September 30, 2026, FDA generally did not plan to take action against a pharmacy for making GHK-Cu medicines used without injection, provided it met the policy’s conditions.

In FDA’s review list, Category 1 means enough information was submitted for FDA to consider the ingredient; it did not mean approval as of September 30, 2026.

That temporary policy about FDA taking action did not establish that an offered medicine was lawful, as of September 30, 2026.

Ask the pharmacist which conditions apply to the exact medicine offered and how it meets them. The list alone cannot answer that question for you.

An injection

FDA’s page marked current to April 22, 2026 lists GHK-Cu for shots as “nominated but withdrawn”, meaning requests to allow this use in compounding had been taken back.

That withdrawal did not give pharmacies permission to use injected GHK-Cu or put it in Category 1, as checked September 30, 2026.

What was actually studied in people?

Reviews checked September 30, 2026 found few GHK-Cu studies in people; most were small and tested face creams.

A search of ClinicalTrials.gov, the U.S. study register, found no human GHK-Cu injection study on September 30, 2026.

Ask for research on the same ingredient, the same form and the result you want. A question about a cream needs a cream answer.

What remains unanswered?

For injected GHK-Cu, the FDA’s September 30, 2026 information raised concern that the body’s defences could react against the product.

FDA’s September 30, 2026 concern was about the injected material: the peptide may clump together or contain unwanted material that could trigger the body’s defences.

The FDA note did not say where clumps form or describe what the reaction would feel like; information about safety in people was limited as of September 30, 2026.

Because GHK-Cu had no FDA approval, it had no FDA-reviewed instructions listing problems with other medicines or pregnancy information, as of September 30, 2026.

The missing instructions do not answer how it would mix with your medicines. Bring your medicine list and ask what is known about using them together, and what remains unknown.

Ask the prescriber what symptoms would need a call and how to get help.

Turn the evidence into a cost question.

Return to the whole bill